Author:
Sada Pablo Ruiz,Cohen Hannah,Isenberg David
Abstract
Advances in our knowledge of the pathogenic mechanisms of antiphospholipid syndrome have been achieved in the past few years. Apart from the well-known role of anti-β2-glycoprotein I antibodies, complement, endocrine and genetic factors and a variety of other molecules are now under investigation. These new approaches should lead to novel explanations and potential new treatment options.
Publisher
Bentham Science Publishers Ltd.
Reference98 articles.
1. Miyakis S, Lockshin MD, Atsumi T, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
J Thromb Haemost
2006;
4
: 295-306.
2. Cervera R1, Serrano R, Pons-Estel GJ, et al.
Morbidity and mortality in the antiphospholipid syndrome during 10-year period a multicentre prospective study of 1000 patients
Arthritis Rheum
2014.
3. Piette JC, Cacoub P, Wechsler B, et al.
Renal manifestations of the antiphospolipid syndrome
Semin Arthritis Rheum
1994;
23
: 357-66.
4. Nochy D, Daugas E, Droz D, et al.
The intrarenal vascular lesions associated with primary antiphospholipid syndrome.
J Am Soc Nephrolo
1999;
10
: 507-18.
5. Lacueva J, Enriquez R.
Acute renal failure as first clinical manifestation of the primary antiphospholipid syndrome
Nephron
1993;
64
: 479-80.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献